Humana CEO Bruce Broussard gets $323K for commute; Judge approves AmeriHealth's buyout of Chartered Health Plan;

News From Around the Web:

> Humana paid roughly $323,000 for CEO Bruce Broussard to commute to work using the company aircraft, reported the Associated Press. Article

> A D.C. Superior Court judge has approved AmeriHealth Mercy's purchase of Chartered Health Plan for $5 million, the Washington Business Journal reported. The deal is still contingent upon AmeriHealth winning a contract to compete for the Washington, D.C., Medicaid program. Article

> Blue Cross Blue Shield of Massachusetts has signed an alternative quality contract with five-hospital system UMass Memorial Health Care, reported the Worcester Business Journal. Article

Provider News:

> When doctors know patients can see how well they deliver on measures of quality care, they are more motivated to work on improving quality, according to a new study published in the journal Health Affairs. Article

> The Centers for Disease Control and Prevention is calling on providers to help halt the spread of a deadly bacteria that has proven resistant to last-resort antibiotics. Article

Health IT News

> Three out of four healthcare providers say their ICD-10 implementation process is only 25 percent or less complete and one-third have not yet started the process, according to a study by healthcare consultants Aloft Group. Article

> The AIDS United Foundation has awarded a $525,000 grant to the University of Virginia School of Medicine to develop a smartphone app to help provide critical support to people diagnosed with HIV in rural Virginia. Article

And Finally… Genetic disorders can't fool this female insect. Article

Suggested Articles

Healthcare leaders say the pandemic could prove to be the tipping point for digital health tools that can help manage patients outside hospitals.

As a health plan built on tech, Oscar Health was uniquely positioned to respond to the COVID-19 pandemic. 

Drugs used for ventilator patients—such as sedatives and neuromuscular blockers—are running low.